Clinical results from SpectraCure’s fourth patient treatment
The fourth patient in the clinical phase 1 trial that SpectraCure is running for treatment of patients with recurrent prostate cancer was conducted, as previously communicated, on February 22th. The treatment was performed using the method for photodynamic therapy (PDT) that SpectraCure has developed. From the MRI of the prostate acquired a week after treatment, […]
British Medicines Agency MHRA approves clinical study
SpectraCure's application for completing parts of an ongoing Phase 1 clinical trial in the UK has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The study is the same Phase 1 study conducted by SpectraCure for the treatment of prostate cancer at the Princess Margaret Cancer Center in Toronto, Canada. With […]
New patient treatment in the clinical phase 1 study
The fourth patient has been treated on February 22, 2018 in the Phase 1 study conducted by SpectraCure for the treatment of patients with relapse of prostate cancer. The treatment was performed at Princess Margaret Cancer Centre in Toronto, Canada, and passed without complications and the patient is doing well. The treatment method, called Photodynamic […]
SpectraCure initiates process for change of listing
The Board of SpectraCure AB ("SpectraCure" or the "Company") has decided to initiate a process for change of listing, from AktieTorget to Nasdaq First North Premier. The company's ambition is to implement the list change to Nasdaq First North Premier during 2018. A listing on First North Premier is expected to create favorable conditions for […]
SpectraCure at G&W Capital Market Day, 2018
SpectraCures CEO Masoud Khayyami will present the company, including the status of the ongoing clinical study, at G&W Capital Market Day on February 23th, at 10:00 AM. Location: Berns Salonger, Kammarsalen, Berzelii Park, Stockholm The presentation can also be followed via webcast at https://tv.streamfabriken.com/2018-02-23-spectracure For further information, contact:SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 […]
Scientific and technical meetings at SPIE Photonics West
Staff from SpectraCure attended the SPIE’s conference BiOS – Photonics West in San Francisco in late January. Among other things, the partners of SpectraCure at the University of Pennsylvania presented results for the treatment of pleural cancer. The results confirmed that the real time-monitoring of optical properties, photosensitiser and oxygen supply during photodynamic treatment (PDT) […]
SpectraCure to participate in a large research programme funded by Knut and Alice Wallenberg Foundation
SpectraCure will be an industrial participant in a large research programme in quantum technology, WACQT – Wallenberg Center for Quantum Technology, funded mainly by Knut and Alice Wallenberg Foundation. SpectraCure will receive funding to pay the salary of a researcher at the research school for PhD students covered by the program. The researcher will be […]
Patent for treatment consumable approved in Canada
The Canadian Patent Office has granted a patent for a consumable used in conjunction with SpectraCure's technology for the treatment of prostate cancer with photodynamic therapy (PDT). The sterile disposable item consists of a combined insertion needle and optical fibre, used to deliver the laser light to the cancer tumour inside the body. – It […]
Results and strategies of the clinical studies were discussed with the responsible physician
On November 21st SpectraCure arranged a meeting where, among others, Dr. Neil Fleshner participated. Dr. Fleshner is a professor at the division of urology at the University of Toronto and the responsible Uro-oncologist at the Princess Margaret Cancer Centre in Toronto where the first three patients in the company's clinical Phase 1 study were treated. […]
PSA-values from clinical prostate trial mentioned on SpectraCure presentation at ”Stora Aktiedagen” in Stockholm
On November 13, SpectraCure made a company presentation when Aktiespararna arranged “Stora Aktiedagen” at Sheraton Hotel in Stockholm. SpectraCure are currently performing a clinical Phase 1 trial for treatment of patients with recurrent prostate cancer, using the company’s tumour treatment technique photodynamic therapy (PDT). During the presentation, Johannes Swartling, CTO at SpectraCure, mentioned that the […]
